Cambiar Investors LLC bought a new stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 251,763 shares of the company’s stock, valued at approximately $39,023,000. Johnson & Johnson makes up approximately 1.7% of Cambiar Investors LLC’s holdings, making the stock its 23rd largest holding.
Other hedge funds have also modified their holdings of the company. GW&K Investment Management LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at about $35,000. Dark Forest Capital Management LP increased its holdings in shares of Johnson & Johnson by 1,044.4% in the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after purchasing an additional 188 shares during the period. Ruedi Wealth Management Inc. acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at about $42,000. Kepos Capital LP acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at about $45,000. Finally, VitalStone Financial LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth about $52,000. 67.57% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the sale, the insider now owns 87,747 shares of the company’s stock, valued at $15,092,484. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the sale, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at $10,549,440. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at $15,092,484. The disclosure for this sale can be found here. Insiders sold a total of 47,163 shares of company stock valued at $7,928,856 over the last quarter. 0.20% of the stock is owned by insiders.
Johnson & Johnson Stock Performance
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Thursday, July 20th. The company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The firm had revenue of $25.53 billion for the quarter, compared to the consensus estimate of $24.63 billion. During the same quarter last year, the business posted $2.59 earnings per share. The firm’s revenue was up 6.3% compared to the same quarter last year. On average, research analysts predict that Johnson & Johnson will post 10.75 EPS for the current year.
Johnson & Johnson Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be paid a dividend of $1.19 per share. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 annualized dividend and a yield of 2.75%. Johnson & Johnson’s dividend payout ratio (DPR) is 96.36%.
Wall Street Analyst Weigh In
JNJ has been the topic of several analyst reports. JPMorgan Chase & Co. raised their target price on Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Raymond James raised their target price on Johnson & Johnson from $181.00 to $184.00 and gave the stock an “outperform” rating in a report on Monday, July 24th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Monday, July 31st. Credit Suisse Group raised their target price on Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Finally, TheStreet lowered Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, May 19th. Eight investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $171.80.
Check Out Our Latest Stock Report on Johnson & Johnson
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- On Holding Slips Into A More Comfortable Price Point
- How to Invest in the Entertainment Industry
- 3 Growing Cannabis Stocks Ready To Bloom
- Why Invest in 5G? How to Invest in 5G Stocks
- Will Meta’s Pullback Offer Buy Point After AI-Driven Surge?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
